Scientists at the Institute of Cancer Research (ICR) in London have discovered that melanoma cells spread by harnessing a gene normally involved in the development of the nervous system. Read More
GentiBio announced that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered regulatory T cell (Treg) therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). Read More
Vellore Institute of Technology University (VIT) and BG Negev Technologies and Applications have described new curcumin or piperine analogues acting as NF-kappaB (NFKB) activation inhibitors and/or quorum sensing signaling inhibitors reported to be useful for treatment of cancer, fungal and bacterial infections and inflammatory disorders. Read More
RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer. Read More
WuXi Biologics (Shanghai) and WuXi Biologics Ireland have divulged antibody-drug conjugates (ADCs) comprising anti-TROP2 antibodies covalently linked to cytotoxic drugs via linker reported to be useful for the treatment of cancer. Read More
Schroedinger has patented fused heterocycles acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer. Read More
Alexion Pharmaceuticals has synthesized new macrocycle compounds acting as complement factor B inhibitors reported to be useful for the treatment of age-related macular degeneration, multiple sclerosis, rheumatoid arthritis, retinal degeneration, chronic obstructive pulmonary disease (COPD), paroxysmal nocturnal hemoglobinuria and cardiovascular disorders. Read More
Cure Rare Disease (CRD) announced that the FDA has approved the first-in-human IND for CRD-TMH-001, its first therapeutic candidate using CRISPR-transactivator technology to treat a rare mutation causing Duchenne muscular dystrophy. Read More
Aro Biotherapeutics announced that the FDA has granted orphan drug designation for ABX-1100, its investigational Centyrin-siRNA conjugate, for the treatment of Pompe disease. Read More
DexTech Medical announced that its application for a phase I clinical trial of OsteoDex in patients with multiple myeloma has been submitted to the Medical Products Agency on June 23, 2022 and it has been approved and granted permission August 10, 2022. Read More
